Active specific immunotherapy with therapeutic melanoma vaccines
HAYES, Inc.
Record ID 32004000346
English
Authors' objectives:
Active specific immunotherapy with therapeutic melanoma vaccines is proposed for selected categories of patients with malignant melanoma. The goals of treatment with melanoma vaccines include tumor regression, prolongation of disease-free and overall survival, and improved quality of life. Active specific immunotherapy is designed to elicit an immune response by recruiting specific effector cells to produce antibodies or a T-cell response directed against one or more specific tumor antigens. This is in contrast to active immunotherapy using nonspecific agents, such as cytokines, that stimulate the immune system globally; and passive immunotherapy with agents, such as monoclonal antibodies, that directly or indirectly mediate tumor killing.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com/
Year Published:
2000
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Immunotherapy
- Immunotherapy, Active
- Melanoma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.